This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.00% per year. These returns cover a period from January 1, 1988 through May 4, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
biotechs: Archive
Novo Nordisk Stock Up as UK Wegovy Pill Nod Eclipses Security Breach
by Zacks Equity Research
NVO stock gains 3% as the United Kingdom becomes Europe's first country to approve the daily GLP-1 Wegovy weight-loss pill, overshadowing an IT security breach.
NVOPositive Net Change LQDANegative Net Change IMCRNegative Net Change INDVNegative Net Change
biotechnology biotechs medical pharmaceuticals
Pharma and Biotech M&A Boom Accelerates as Companies Expand Pipelines
by Ekta Bagri
Pharma and biotech dealmaking is surging in 2026 as companies pursue acquisitions to expand pipelines, strengthen portfolios and drive growth.
GSKNegative Net Change NVSNegative Net Change MRKNegative Net Change LLYPositive Net Change GILDNegative Net Change
biotechnology biotechs medical pharmaceuticals
Novartis Reports Positive Data for Neuromuscular Disorder Drug
by Zacks Equity Research
NVS announces positive FORTITUDE data as del-brax met key endpoints, supporting its potential as a disease-modifying treatment for FSHD.
NVSNegative Net Change RHHBYNegative Net Change BAYRYPositive Net Change
biotechnology biotechs medical pharmaceuticals
Puma Biotechnology Stock Rises 19% in 3 Months: Here's Why
by Zacks Equity Research
PBYI's shares rally 19% in three months as rising Nerlynx demand and a raised 2026 revenue outlook boost investor confidence.
RHHBYNegative Net Change PBYINegative Net Change LQDANegative Net Change IMCRNegative Net Change
biotechs
HROW Stock Rises on Relaunch of Ophthalmology Drug Verkazia in the US
by Zacks Equity Research
Harrow shares gain after relaunching Verkazia in the United States, aiming to improve access to an FDA-approved VKC treatment for pediatric patients.
LQDANegative Net Change HROWPositive Net Change IMCRNegative Net Change INDVNegative Net Change
biotechs
Will Skyrizi & Rinvoq Continue to Drive AbbVie's Topline Through 2026?
by Zacks Equity Research
ABBV's Skyrizi and Rinvoq post strong Q1 growth, lift 2026 sales outlooks and sustain momentum through new indications.
JNJNegative Net Change LLYPositive Net Change ABBVNegative Net Change
biotechs medical pharmaceuticals
EMA Begins Review of Bayer's Asundexian Filing for Stroke Prevention
by Zacks Equity Research
BAYRY's asundexian enters EMA review for stroke prevention after phase III data showed a 26% cut in ischemic stroke without more major bleeding.
BAYRYPositive Net Change LQDANegative Net Change IMCRNegative Net Change INDVNegative Net Change
biotechnology biotechs medical pharmaceuticals
Roche's Tecentriq Plus Chemo Gets FDA Priority Tag for Colon Cancer
by Zacks Equity Research
RHHBY wins FDA priority review for Tecentriq plus FOLFOX6 in stage III dMMR/MSI-H colon cancer, with a decision due in October 2026.
RHHBYNegative Net Change LQDANegative Net Change IMCRNegative Net Change INDVNegative Net Change
biotechs
Can Gilead Sciences HIV Franchise Drive Long-Term Growth?
by Zacks Equity Research
Gilead's HIV franchise gains momentum as Biktarvy and Descovy drive growth, Yeztugo outlook rises, and late-stage pipeline advances.
GSKNegative Net Change MRKNegative Net Change GILDNegative Net Change
biotechnology biotechs medical pharmaceuticals
Should You Buy ANI Pharmaceuticals at 9.8x Forward Earnings?
by Sundeep Ganoria
ANIP trades at 9.75x forward earnings after raising 2026 guidance, but investors must weigh Cortrophin-led growth against competition and customer concentration.
REGNPositive Net Change ABBVNegative Net Change ANIPNegative Net Change HRMYNegative Net Change
biotechs medical pharmaceuticals